Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDS
Go back to Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDS| (NASDAQ: VERU) | Delayed: 2.83 -0.23 (7.52%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.06 | 52 Week High | $ | |||
| Open | $2.99 | 52 Week Low | $ | |||
| Day High | $2.99 | P/E | N/A | |||
| Day Low | $2.70 | EPS | $ | |||
| Volume | 380,890 | |||||
